Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Oncolytics Biotech Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== '''Board of Directors at Oncolytics Biotech.:''' === '''Matt Coffey, PhD, MBA''' is a '''Director''' in Oncolytics and completed his PhD at the University of Calgary in oncology, specifically focusing on reoviruses. Matt Coffey published many successful research papers before he cofounded Oncoltyics Biotech. Within the company, Coffey excelled in various roles including Chief executive officer, Chief operating officer, Chief scientific officer and Vice President of Product development and Chief financial officer. '''Wayne Pisano''' is a '''Director''' at Oncolytics and has had a very successful career and been recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He has served a plethora of roles including: President and CEO of VaxInnate (a privately held biotech company), member of Immunovaccine's Board in October 2011 and lastly he was the former President and CEO of Sanofi Pasteur (one of the largest vaccine companies in the world). '''Jonathan Rigby''' is a '''Director''' at Oncolytics. He is currently the Group Chief Executive Officer of Revolo Biotherapeutics, where he is focused on the development of therapies for autoimmune and allergic diseases. Other than this he has lots of experience in the biotech industry including CEO of SteadyMed Ltd, Co-founding Zogenix, Inc. (a CNS-focused specialty pharmaceutical company), being a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and lastly the Chairman of BIOS (a Nasdaq-listed biotech acquisition company). '''Deborah M. Brown, MBA''' is a '''Director''' at Oncolytics. Ms. Brown has many achievements including being a current Managing Partner at Accelera (a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe) Canada. She has previously been Executive Vice President of Neuroimmunology and President and Managing Director of the company's Canadian operations at EMD Serono. Ms. Brown has also been Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada), Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. '''Bernd R. Seizinger, MD, PhD''' is a '''Director''' at Oncolytics. Dr. Bernd., currently serves as board member in numerous public and private biotech companies including: Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. In previous roles he was simultaneously President & CEO of GPC Biotech (VP Oncology Drug Discovery) while also serving as VP Corporate and Academic Alliances at Bristol-Myers Squibb, and as Executive VP and CSO of Genome Therapeutics. Prior to his corporate appointments, he held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University. '''James T. Parsons''' is a '''Director''' at Oncolytics. His executive experience includes, currently, being Chief Financial Officer of Trillium Therapeutics Inc. Previosuly he has been president of Empar Management, Vice President of Finance at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President of Finance and Administration at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons has also been a Director and the Chair of the Audit Committees of Sernova Corp. and DiaMedica Therapeutics Inc. '''Angela Holtham, MBA,''' is a '''Director''' at Oncolytics. She is currently the Senior Vice President and Chief Financial Officer of Canadian subsidiary of Nabisco Inc. She has also been the Vice President, Finance and Chief Financial Officer in the Ontario-based Hospital for Sick Children.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)